Literature DB >> 20951918

Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.

Irene Sonu1, Ming Valerie Lin, Wojciech Blonski, Gary R Lichtenstein.   

Abstract

Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20951918     DOI： 10.1016/j.gtc.2010.08.011

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  10 in total

Review 1.  Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs.

Authors:  Jennifer Poh; Sandra Knowles
Journal:  Can J Hosp Pharm       Date:  2014-01

Review 2.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  Design, Synthesis, and Testing of a Molecular Truck for Colonic Delivery of 5-Aminosalicylic Acid.

Authors:  Suryakiran Navath; Venkataramanarao Rao; Rita-Marie T Woodford; Monica T Midura-Kiela; Ali M Ahad; Ramesh Alleti; Pawel R Kiela; Eugene A Mash
Journal:  ACS Med Chem Lett       Date:  2012-08-01       Impact factor: 4.345

Review 5.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

Review 6.  Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.

Authors:  Wei-Qun Mei; Hui-Zhen Hu; Ying Liu; Zhi-Chen Li; Wei-Guo Wang
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

7.  Red-Brown Urine Discolouration in Two Patients Taking Mesalamine.

Authors:  Tim Smeets; Florence van Hunsel
Journal:  Drug Saf Case Rep       Date:  2016-12

Review 8.  Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Korean J Intern Med       Date:  2022-07-27       Impact factor: 3.165

9.  Mesalamine-induced eosinophilic pleural effusion.

Authors:  Abdullah Al-Abcha; Fazal Raziq; Shouq Kherallah; Ahmad Alratroot
Journal:  BMJ Case Rep       Date:  2020-04-16

10.  Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity.

Authors:  Aurelio Romero-Castro; Mara Gutiérrez-Sánchez; José Correa-Basurto; Martha Cecilia Rosales Hernández; Itzia Irene Padilla Martínez; Jessica Elena Mendieta-Wejebe
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.